Entrada Therapeutics (TRDA) Retained Earnings (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Retained Earnings of -$312.8 million for Q1 2026, down 113.23% year-over-year from $2.4 billion in Q1 2025, and down 48077.15% quarter-over-quarter from $652000.0 in Q4 2025.
Entrada Therapeutics (TRDA) Retained Earnings (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Retained Earnings history runs 7 years deep, the most recent figure standing at -$312.8 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 113.23% year-over-year to -$312.8 million; the TTM figure through Mar 2026 stood at -$312.8 million (down 113.23% YoY), while the FY2025 annual figure was $652000.0, up 100.5% from the prior year.
- Retained Earnings for Q1 2026 stood at -$312.8 million, down from $652000.0 in the prior quarter.
- The five-year high for Retained Earnings was $441.1 million in Q1 2024, with the low at -$312.8 million in Q1 2026.
- The 5-year median for Retained Earnings is $621000.0 (2025), against an average of $111.8 million.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings soared 27800.98% in 2023, then plunged 66430.26% in 2024.
- Entrada Therapeutics' Retained Earnings stood at $402.9 million in 2022, then slumped by 99.95% to $195000.0 in 2023, then slumped by 66430.26% to -$129.3 million in 2024, then soared by 100.5% to $652000.0 in 2025, then slumped by 48077.15% to -$312.8 million in 2026.
- Business Quant data shows TRDA's Retained Earnings at -$312.8 million in Q1 2026, $652000.0 in Q4 2025, and $621000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - | 588.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 588.92 Mn |
| Mar 31, 2026 | -312.81 Mn |
| Dec 31, 2025 | 652,000.00 |
| Sep 30, 2025 | 621,000.00 |
| Jun 30, 2025 | -189.80 Mn |
| Mar 31, 2025 | -146.70 Mn |
| Dec 31, 2024 | -129.34 Mn |
| Sep 30, 2024 | -130.48 Mn |
| Jun 30, 2024 | -116.40 Mn |
| Mar 31, 2024 | 441.08 Mn |
| Dec 31, 2023 | 195,000.00 |
| Sep 30, 2023 | 432.58 Mn |
| Jun 30, 2023 | 428.80 Mn |
| Mar 31, 2023 | 425.21 Mn |
| Dec 31, 2022 | 402.89 Mn |
| Sep 30, 2022 | 399.62 Mn |
| Jun 30, 2022 | 396.82 Mn |
| Mar 31, 2022 | -1.54 Mn |
| Dec 31, 2021 | -93.67 Mn |
| Sep 30, 2021 | 2.63 Mn |